|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2200066237 |
|
最近更新日期: Date of Last Refreshed on: |
2023-05-03 14:38:03 |
|
注册时间: Date of Registration: |
2022-11-29 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
rTMS刺激DLPFC对脑卒中患者双重任务步行能力的影响与机制探索 |
|
Public title: |
Effect and mechanism exploration of DLPFC stimulation by rTMS on dual-task walking ability in people with stroke |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
rTMS刺激DLPFC对脑卒中患者双重任务步行能力的影响与机制探索 |
|
Scientific title: |
Effect and mechanism exploration of DLPFC stimulation by rTMS on dual-task walking ability in people with stroke |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
蔺小英 |
研究负责人: |
杨磊 |
|
Applicant: |
Lin Xiaoying |
Study leader: |
Yang Lei |
|
申请注册联系人电话: Applicant telephone: |
18406565037 |
研究负责人电话:
Study leader's |
13529435568 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
2043307072@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
leon_yang30@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
云南省昆明市五华区滇缅大道374号昆明医科大学第二附属医院 |
研究负责人通讯地址: |
昆明市盘龙区龙泉路871号昆明市第二人民医院康复医学科 |
|
Applicant address: |
The Second Affiliated Hospital of Kunming Medical University, No. 374 Yunnan Burma Avenue, Wuhua District, Kunming City, Yunnan Province |
Study leader's address: |
The Second People’s Hospital of Kunming, No. 871 longquan Road, Panlong District, Kunming city |
|
申请注册联系人邮政编码: Applicant postcode: |
650000 |
研究负责人邮政编码: Study leader's postcode: |
650000 |
|
申请人所在单位: |
昆明医科大学第二附属医院 |
||
|
Applicant's institution: |
The Second Affiliated Hospital of Kunming Medical University |
||
|
研究负责人所在单位: |
昆明市第二人民医院 |
||
|
Affiliation of the Leader: |
The Second People’s Hospital of Kunming |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2022年第02号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
昆明市第二人民医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of The Second People’s Hospital of Kunming |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2022-03-09 00:00:00 | ||
|
伦理委员会联系人: |
石晓琳 |
||
|
Contact Name of the ethic committee: |
Shi Xiaolin |
||
|
伦理委员会联系地址: |
昆明市盘龙区龙泉路871号昆明市第二人民医院 |
||
|
Contact Address of the ethic committee: |
The Second People’s Hospital of Kunming, No. 871 longquan Road, Panlong District, Kunming city |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
13708893587 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
昆明市第二人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Second People’s Hospital of Kunming |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
昆明市盘龙区龙泉路871号昆明市第二人民医院 |
||||||||||||||||||||||
|
Primary sponsor's address: |
The Second People’s Hospital of Kunming, No. 871 longquan Road, Panlong District, Kunming city |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
昆明市卫生科技人才培养项目,项目编号:2022-SW-27 |
||||||||||||||||||||||
|
Source(s) of funding: |
Kunming Health Science and technology talent training project, Project No.: 2022-SW-27 |
||||||||||||||||||||||
|
研究疾病: |
脑卒中 |
||||||||||||||||||||||
|
Target disease: |
Stroke |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
(1)明确rTMS刺激DLPFC对卒中患者DT能力的影响,并确立该方法在卒中康复治疗中的应用价值; (2)揭示rTMS刺激DLPFC对卒中患者DT功能相关脑区的影响; (3)揭示rTMS刺激DLPFC对卒中患者DT功能相关脑功能连接的影响; (4)探索卒中康复过程中,认知功能与运动功能的相互影响关系及与脑区激活的相关性。 |
||||||||||||||||||||||
|
Objectives of Study: |
(1) To determine the effect of rTMS of DLPFC on DT function of people with stroke, and to establish the application value of this method in stroke rehabilitation; (2) To reveal the effect of rTMS of DLPFC on DT function related brain regions in people with stroke; (3) To reveal the effect of rTMS of DLPFC on DT related brain functional connectivity in people with stroke; (4) To explore the interaction between cognitive function and motor function and the correlation with brain activation in the process of stroke rehabilitation. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
①符合中华医学会神经病学分会血管病学组制定的《中国各类主要脑血管病诊断要点2019》中对脑梗死或脑出血的诊断标准;②年龄在30~80岁之间;③首次发病且病程超过1个月;④单侧脑卒中,须经颅脑电子计算机断层扫描或磁共振成像证实;⑤能执行简单指令;⑥能独立步行至少10米。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. It meets the diagnostic criteria for cerebral infarction or cerebral hemorrhage in the key points for diagnosis of various major cerebrovascular diseases in China 2019 formulated by the vascular diseases group of the neurology branch of the Chinese Medical Association; |
||||||||||||||||||||||
|
排除标准: |
①存在脑卒中以外的其他神经系统疾病(包括颅脑外伤);②小脑或脑干损伤;③存在TMS禁忌证的受试者,如戴有心脏起搏器、颅内有金属植入物或有颅骨缺损、既往有癫痫病史、妊娠等;④严重的认知或言语障碍;⑤合并心、肺、肝、肾等重要脏器功能障碍或其他严重躯体疾病;⑥拒绝参与试验或签署知情同意书。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Other nervous system diseases other than stroke (including craniocerebral trauma); |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2022-07-01 00:00:00至 To 2025-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2022-07-01 00:00:00 至 To 2025-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
研究为前瞻性、单中心、双盲随机对照试验,由一名不知情的研究人员采用随机数字表法进行随机分组,以1:1的分配比例随机分成试验组和对照组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The study is a prospective, single center, double-blind randomized controlled trial. An uninformed researcher randomly divided the subjects into the experimental group and the control group by using the random number table method, and randomly divided them into the experimental group and the control group . |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
试验过程中对受试者和评估者实施盲法,试验实施者非盲 |
|
Blinding: |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
2026年12月31日之前公布于中国临床试验注册中心平台,数据公开方式将采用ResMan (http://www.medresman.org.cn/) |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
ResMan (http://www.medresman.org.cn/) |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集由本研究内研究人员(非试验操作者)进行采集,形成纸质版评估表,再上传至电子采集与管理系统即ResMan。 ResMan (http://www.medresman.org.cn/) |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection is carried out by researchers (non operators) in this study to form a paper version of the evaluation form, which is then uploaded to the electronic data capture, namely resman. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |